Single Cell Analysis Market Expected to Reach $13.62 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Single Cell Analysis Market," The single cell analysis market was valued at $2.64 billion in 2021, and is estimated to reach $13.62 billion by 2031, growing at a CAGR of 17.8% from 2022 to 2031.

Single-cell analysis refers to the analysis of a single-cell genome or transcriptome, so as to obtain genomic, transcriptome or other multi-omics information to reveal cell population differences and cellular evolutionary relationships. Traditional analysis methods can only get the average of many cells, unable to analyse a small number of cells and lose cellular heterogeneity information. As compared to traditional analysis technology, single-cell technologies have the advantages of detecting heterogeneity among individual cells, distinguishing a small number of cells, and delineating cell maps. Nowadays, single-cell sequencing technology is increasingly used in various fields including tumours, microbiology, neurology, reproduction, immunity, digestion, and urinary systems.

The key factors that drive the growth of the single cell analysis market size are technological advancement in single cell analysis coupled with increase in R&D in pharmaceutical and biotechnology industry. In addition, growth in stem cell research, rise in focus on personalized medicines and surge in prevalence of cancer are some single cell analysis market trends which further expected to boost the market growth during forecast period. However, higher cost of single cell analysis products is likely to hamper the single cell analysis market growth during the forecast period. Conversely, high growth potential of single cell sequencing is expected to provide numerous opportunities for market growth during the forecast period.

The single cell analysis market is segmented into product, application, techniques, end user and region. According to product, the market is categorized into consumables and instruments. By application, it is segregated into oncology, immunology, neurology, stem cell, non-invasive prenatal diagnosis, In-vitro fertilization, others. According to techniques, the market is categorized into flow cytometry, next generation sequencing, polymerase chain reaction, mass spectrometry and others.  On the basis of end user, it is segmented into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

By product, the consumable segment dominated the single cell analysis market share in 2021 and is expected to remain dominant during the forecast period, owing to high usability of products and frequent purchase of reagents, increase in prevalence of target diseases and constant need for consumables required for assay.

Depending on application, the oncology segment dominated the market in 2021 and is expected to remain dominant during the forecast period, owing to increase in prevalence of cancer. In addition, single cell analysis proved to be effective for prior diagnostics of cancer cells, thus driving the segment growth. However, neurology segment registered highest CAGR during forecast period, owing to increase in prevalence of neurological disorders.

By technique, the next generation sequencing segment dominated the market in 2021 and is expected to remain dominant during the forecast period, owing to increase in genome mapping programs, rise in applications of next generation sequencing, increase in healthcare expenditure and technological advancements in sequencing platforms.

On the basis of end user, the biotechnology and pharmaceutical industries segment dominated the market in 2021 and is expected to remain dominant during the forecast period, owing to technological advancement such as the use of microfluidics for the development of next generation therapies have increased the adoption of single cell analysis by biotechnology and pharmaceutical companies. Moreover, increase in penetration of genomic technologies in drug development is expected to further drive the market. 

Region wise, North America has the highest market share in 2021, and is estimated to register a CAGR of 14.7% during the forecast period owing to the well-established healthcare system, increase in number of geriatric patients, presence of key market players, supportive reimbursement policies in healthcare system. In addition, increase in R&D expenditure and federal funding further boost the market growth. Europe is projected to register the highest CAGR of 21.6% during the forecast period. The increasing per capita income, growing medical tourism industry, and rising public awareness regarding benefits of single cell analysis are the key driving factors that boost the growth of the market in the region.

KEY FINDINGS OF STUDY
• On the basis of product, the consumables segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
• On the basis of application, the oncology segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
• On the basis of technique, the next generation sequencing segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
• Depending on end user, biotechnology and pharmaceutical companies' segment is projected to grow at a CAGR of 17.6% during the forecast period.
• Region-wise, North America garnered the largest revenue share in cell analysis industry in 2021. However, Europe is anticipated to grow at the highest CAGR 21.6% during the forecast period.